Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways

BACKGROUND: Standard chemotherapy protocols in NSCLC are of limited clinical benefit. Histone deacetylase (HDAC) inhibitors represent a new strategy in human cancer therapy. In this study the combination of the HDAC inhibitor phenylbutyrate (PB) and the nucleoside analogue gemcitabine (GEM) was eval...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schniewind, Bodo, Heintz, Kirsten, Kurdow, Roland, Ammerpohl, Ole, Trauzold, Anna, Emme, Doris, Dohrmann, Peter, Kalthoff, Holger
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2006
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1665446/
https://ncbi.nlm.nih.gov/pubmed/17123441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-3163-5-25
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados